Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Depression and Alzheimer's disease: Symptom or comorbidity?
Alzheimer 's disease is the most frequent form of dementia , where behavioral and cognitive disruption symptoms coexist . Depression , apathy , anxiety , and other conduct disorders are the complaints most often reported by caregivers . Fifty subjects were referred to our Institute with a diagnosis of probable Alzheimer 's disease . Cognitive impairment was equally distributed among the subjects . Patients , aged 68 to 76 years old , were r and omized to receive inhibitors of cholinesterase ( Donepezil , 5 mg/ day ) alone , or inhibitors of cholinesterase plus selective seratonin reuptake inhibitors ( SSRIs ) ( citalopram HBr , 20 mg/day ) . We followed up all the patients for one year , with particular concern for neuropsychological aspects associated with eventual behavioral changes . Results indicate that SSRI intake seems to be effective for depression , decreasing it and improving quality of life for both patients and caregivers . Side effects in both groups were few , and there were no study withdrawals . This paper discusses the relationship between dementia- and depression , and presents our finding that depressive symptoms , if specifically treated , tend to reduce caregiver stress and improve well-being in patients with Alzheimer 's disease
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .